Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 2, 2026, 5:25 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 337–360 of 4,108 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Experimental 2 Clear all
Completed Phase 3 Interventional Accepts healthy volunteers

Lidocaine for Pessary Check Pain Reduction

NCT05493735
View directory record Official record
Conditions
Pelvic Organ Prolapse, Stress Urinary Incontinence
Interventions
Lidocaine Hcl 2% Jelly, Placebo Jelly
Drug
Lead sponsor
University of South Florida
Other
Eligibility
18 Years and older · Female only
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Dec 14, 2023 · Synced Nov 2, 2026, 5:25 AM EST
Completed Phase 3 Interventional

Open Label Trial Assessing Safety and Efficacy of Burosumab (KRN23), in a Patient With ENS and Hypophosphatemic Rickets

NCT03581591
View directory record Official record
Conditions
Hypophosphatemia, Hypophosphatemic Rickets, Pain, Chronic
Interventions
Burosumab
Biological
Lead sponsor
Redwood Dermatology Sciences
Other
Eligibility
Up to 18 Years · Female only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Clinton, Utah
Source: ClinicalTrials.gov public record
Updated Jan 18, 2020 · Synced Nov 2, 2026, 5:25 AM EST
Completed Not applicable Interventional

The Effect of Non-Surgical Periodontal Therapy on Glycemic Control and Bacterial Levels in a Mexican-American Population With Type 2 Diabetes

NCT01128374
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Periodontal Disease
Interventions
Periodontal Scaling and root planing
Procedure
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 15, 2013 · Synced Nov 2, 2026, 5:25 AM EST
Terminated Not applicable Interventional Results available

Safety, Efficacy, Longitudinal Costs and Patient-Centered Outcomes Using a TAAA Debranching Device

NCT03637374
View directory record Official record
Conditions
Thoracoabdominal Aortic Aneurysm
Interventions
Visceral Manifold and Thoracic Bifurcation, Unitary Manifold, TAAA Debranching Stent Graft System
Device
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 19, 2022 · Synced Nov 2, 2026, 5:25 AM EST
Completed Phase 2 Interventional

A Study to Compare FCD105 Foam to Minocycline 3% Foam, Adapalene 0.3% Foam and Vehicle Foam.

NCT04104685
View directory record Official record
Conditions
Acne Vulgaris
Interventions
FCD105, 3% Minocycline Foam, 0.3% Adapalene Foam, Vehicle Foam
Combination Product · Drug · Other
Lead sponsor
Vyne Therapeutics Inc.
Industry
Eligibility
12 Years and older
Enrollment
446 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
35
States / cities
Bryant, Arkansas • Rogers, Arkansas • Encino, California + 32 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2021 · Synced Nov 2, 2026, 5:25 AM EST
Active, not recruiting Phase 3 Interventional Accepts healthy volunteers

Study of the Safety and Immunogenicity of Catch-up Vaccination With a 21-valent Pneumococcal Conjugate Vaccine (PCV21) in Healthy Infants, Toddlers, Children, and Adolescents

NCT06838000
View directory record Official record
Conditions
Pneumococcal Infections
Interventions
PCV21, 20vPCV
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
7 Months to 17 Years
Enrollment
1,268 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
17
States / cities
Paramount, California • Doral, Florida • Hialeah, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2025 · Synced Nov 2, 2026, 5:25 AM EST
Active, not recruiting Phase 1Phase 2 Interventional

A Study of Efficacy and Safety of Pembrolizumab Plus Enfortumab Vedotin (EV) +/- Investigational Agents in First-Line Metastatic Urothelial Carcinoma (mUC) (MK-3475-04B/KEYMAKER-U04)

NCT05845814
View directory record Official record
Conditions
Metastatic Urothelial Carcinoma, Urothelial Neoplasms
Interventions
Coformulated favezelimab/pembrolizumab, Coformulated vibostolimab/pembrolizumab, EV, Pembrolizumab
Biological · Combination Product
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
390 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
14
States / cities
La Jolla, California • Orange, California • San Francisco, California + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2025 · Synced Nov 2, 2026, 5:25 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

Impact of New Standards for Tobacco Products Among Dual E-Cigarette/Combusted Cigarette Users - Project 2

NCT05473585
View directory record Official record
Conditions
Smoking, Smoking, Cigarette, E-Cig Use, Nicotine Dependence
Interventions
very low nicotine content cigarettes, normal nicotine content cigarettes, Study e-cigarette
Other
Lead sponsor
Duke University
Other
Eligibility
21 Years and older
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 19, 2023 · Synced Nov 2, 2026, 5:25 AM EST
Completed Phase 1 Interventional

A Study of Single and Repeat Dose Administration of UBX0101 in Patients With Osteoarthritis of the Knee

NCT04229225
View directory record Official record
Conditions
Knee Osteoarthritis
Interventions
UBX0101, Placebo
Drug · Other
Lead sponsor
Unity Biotechnology, Inc.
Industry
Eligibility
40 Years to 85 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
7
States / cities
The Villages, Florida • Marietta, Georgia • St Louis, Missouri + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2020 · Synced Nov 2, 2026, 5:25 AM EST
Completed Phase 4 Interventional Results available

A Multicenter Study to Assess Response to Influenza Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab

NCT04667117
View directory record Official record
Conditions
Relapsing Multiple Sclerosis
Interventions
Quadrivalent influenza vaccine, Ofatumumab, iDMT
Biological · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
3
States / cities
Phoenix, Arizona • Hollywood, Florida • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 9, 2024 · Synced Nov 2, 2026, 5:25 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

The Goodnight Screen Media Study

NCT05820555
View directory record Official record
Conditions
Sleep, Sleep Hygiene
Interventions
Timed evening technology and digital media use (tablet use), no technology and digital media use (screen media use)
Behavioral
Lead sponsor
Baylor College of Medicine
Other
Eligibility
48 Months to 59 Months
Enrollment
170 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 5, 2026 · Synced Nov 2, 2026, 5:25 AM EST
Recruiting Phase 1 Interventional Accepts healthy volunteers

The Impact of Light Exposure on Cognitive Function in Classrooms

NCT06325150
View directory record Official record
Conditions
Healthy
Interventions
Light emitting glasses
Device
Lead sponsor
Michigan State University
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
East Lansing, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Nov 2, 2026, 5:25 AM EST
Recruiting Phase 4 Interventional

Measuring the Effect of Dupilumab Treatment on Mucociliary Clearance (MCC) in Subjects With Moderate to Severe Asthma

NCT04743791
View directory record Official record
Conditions
Asthma
Interventions
Dupilumab, Placebo
Drug · Other
Lead sponsor
Sally E. Wenzel MD
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Nov 2, 2026, 5:25 AM EST
Not listed No phase listed Observational

LONG TERM EFFECTS OF SPINAL CORD STIMULATION

NCT06272955
View directory record Official record
Conditions
Parkinson Disease
Interventions
Spinal Cord Stimulator (SCS)
Device
Lead sponsor
Nora Vanegas
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 22, 2024 · Synced Nov 2, 2026, 5:25 AM EST
Terminated Phase 1 Interventional Results available

Intraperitoneal Infusion of Autologous Monocytes With Sylatron (Peginterferon Alfa-2b) and Actimmune (Interferon Gamma-1b) in Women With Recurrent or Refractory Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer

NCT02948426
View directory record Official record
Conditions
Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cancer
Interventions
Autologous Monocytes + ACTIMMUNE + SYLATRON
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced Nov 2, 2026, 5:25 AM EST
Completed Early Phase 1 Interventional Accepts healthy volunteers

Selective Nerve Stimulation (SNS) Pilot Study

NCT01259271
View directory record Official record
Conditions
Healthy, Pain
Interventions
Selective Nerve Stimulation (SNS) stimulator device
Device
Lead sponsor
Codman & Shurtleff
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Raynham, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 18, 2019 · Synced Nov 2, 2026, 5:25 AM EST
Completed Not applicable Interventional

IPT for Major Depression Following Perinatal Loss: Healing After Loss (HeAL)

NCT04629599
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Interpersonal psychotherapy for major depression following perinatal loss, Coping with Depression
Behavioral
Lead sponsor
Michigan State University
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Flint, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Nov 2, 2026, 5:25 AM EST
Completed No phase listed Observational Accepts healthy volunteers

Agreement and Precision Study of UNITY® DX and a Comparator Biometer

NCT06826599
View directory record Official record
Conditions
Normal Eyes, Abnormal Eyes
Interventions
Investigational Biometer, IOLMaster 700 Biometer
Device
Lead sponsor
Cylite Pty Ltd
Industry
Eligibility
22 Years and older
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Woburn, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 5, 2025 · Synced Nov 2, 2026, 5:25 AM EST
Completed Phase 3 Interventional

Comparing RadiaPlexRx Hydrogel and Standard-of-Care for Radiation Dermatitis in Breast Cancer Patients

NCT00481884
View directory record Official record
Conditions
Radiation Dermatitis
Interventions
RadiaPlexRx Gel, Aquaphor Gel
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Female only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 2, 2016 · Synced Nov 2, 2026, 5:25 AM EST
Completed Phase 2 Interventional

Study of AVB-620 in Women With Primary, Nonrecurrent Breast Cancer Undergoing Surgery

NCT03113825
View directory record Official record
Conditions
Primary Invasive Malignant Neoplasm of Female Breast, Carcinoma Breast, Breast Cancer Female, Carcinoma, Ductal, Breast, Stage II Breast Cancer, Stage I Breast Cancer, Stage III Breast Cancer
Interventions
Investigational Imaging device, AVB-620
Device · Drug
Lead sponsor
Avelas Biosciences, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
13
States / cities
San Diego, California • Washington D.C., District of Columbia • Jacksonville, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2021 · Synced Nov 2, 2026, 5:25 AM EST
Completed Not applicable Interventional Accepts healthy volunteers Results available

A Clinical Trial to Test the Effect of a Marketed Mouth Rinse on Stain Removal

NCT02151058
View directory record Official record
Conditions
Tooth Stain
Interventions
Colgate® Regular Cavity Protection, Experimental Mouth Rinse, Crest® 3D White Multi-Care Whitening Rinse, Glamorous White, Fresh Mint
Drug · Other
Lead sponsor
Johnson & Johnson Consumer and Personal Products Worldwide
Industry
Eligibility
18 Years to 65 Years
Enrollment
227 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Fort Wayne, Indiana
Source: ClinicalTrials.gov public record
Updated Jun 1, 2015 · Synced Nov 2, 2026, 5:25 AM EST
Completed No phase listed Observational Results available

Safety and Effectiveness of BENLYSTA (Belimumab) in Systemic Lupus Erythematosus (SLE) Registry

NCT01729455
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Benlysta, Standard of Care (SoC) Therapy
Biological · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
3,138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2025
U.S. locations
102
States / cities
Birmingham, Alabama • Glendale, Arizona • Goodyear, Arizona + 85 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2026 · Synced Nov 2, 2026, 5:25 AM EST
Recruiting Not applicable Interventional

Targeted Fortification of Donor Breast Milk in Preterm Infants

NCT04294368
View directory record Official record
Conditions
Prematurity; Extreme, Failure to Thrive in Newborn, Growth Retardation, Growth Failure, Infant Nutrition Disorders
Interventions
Similac Human Milk Fortifier Extensively Hydrolyzed Protein Concentrated Liquid, Similac Liquid Protein Fortifier, Nestle Microlipid, Medica Nutrition SolCarb, Similac Human Milk Fortifier Extensively Hydrolyzed Protein Concentrated Liquid (Targeted Fortification), Similac Liquid Protein Fortifier (Targeted Fortification), Nestle Microlipid (Targeted Fortification), Medica Nutrition SolCarb (Targeted Fortification), Analysis with Miris (AB) Human Milk Analyzer
Dietary Supplement · Other
Lead sponsor
Columbia University
Other
Eligibility
1 Day to 21 Days
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Nov 2, 2026, 5:25 AM EST
Completed Early Phase 1 Interventional

Preventing Hypoglycemia During Exercise With Proactive Snacking on Closed Loop

NCT02135068
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Medtronic MiniMed Closed Loop (CL) System, Snacking
Device · Other
Lead sponsor
Yale University
Other
Eligibility
13 Years to 44 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 20, 2020 · Synced Nov 2, 2026, 5:25 AM EST